Scholarly Index
Melinda L. Telli
Stanford University; 18,246 total citations; 211 total publications; best world rank #70
Stanford University
18,246Total citations
211Total publications
53H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| PARP inhibition in cancer therapy | Lifetime | 154 | US 75 | 97.81 |
| Advanced Breast Cancer Therapies | Lifetime | 269 | US 126 | 97.78 |
| HER2/EGFR in Cancer Research | Lifetime | 578 | US 268 | 97.65 |
| BRCA gene mutations in cancer | Lifetime | 430 | US 230 | 97.11 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 188 | US 108 | 95.96 |
| DNA Repair Mechanisms | Lifetime | 962 | US 502 | 96.55 |
| Breast Cancer Treatment Studies | Lifetime | 961 | US 419 | 97.40 |
| DNA Repair Mechanisms | 2021-2025 | 70 | US 28 | 95.30 |
| PARP inhibition in cancer therapy | 2021-2025 | 85 | US 35 | 96.86 |
| Advanced Breast Cancer Therapies | 2021-2025 | 148 | US 53 | 97.42 |
| BRCA gene mutations in cancer | 2021-2025 | 167 | US 78 | 94.17 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 994 | US 355 | 96.21 |
| HER2/EGFR in Cancer Research | 2021-2025 | 393 | US 145 | 93.40 |
| Cancer Treatment and Pharmacology | 2021-2025 | 510 | US 186 | 90.41 |